\ CVR Medical Granted IRB Approval by Thomas Jefferson University Hospital
Company News: Page (1) of 1 - 01/12/17

CVR Medical Granted IRB Approval by Thomas Jefferson University Hospital

January 12, 2017 --
DGAP-News: CVR Medical Corp. / Key word(s): Miscellaneous12.01.2017 / 09:01The issuer is solely responsible for the content of this announcement.---------------------------------------------------------------------------Vancouver, British Columbia--(Newsfile Corp. - January 12, 2017) - CVRMedical Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ('CVR Medical') ispleased to announce that its 'Carotid Stenotic Scan' (CSS) device hasreceived IRB approval for clinical trials, to be conducted through the NIHHF Network at Thomas Jefferson University Hospital under the supervision ofDr. David J. Whellan , MD, MHS, FACC, FAHA.CVR Chief Operations Officer Tony Robinson states, 'With IRB approval, welook forward to continuing our progress through this final phase ofclinical trials. To be able to do so with Dr. Whellan at Thomas Jeffersonis something CVR is very proud of.'For additional information on the organization, leadership, and currentnews please visit the newly launched company website www.CVRMed.comAbout CVR MedicalCVR Medical is a company that is involved in an equal parts joint venturewith CVR Global Inc. (the 'Joint Venture'). The Joint Venture operates inthe medical industry focused on the commercialization of a proprietarysubsonic, infrasonic, and low frequency sound wave analysis technology andhas patents to a diagnostic device designed to detect and measure carotidarterial stenosis. CVR Medical is managed by a proven technical team. CVRMedical trades on the TSX Venture Exchange under the symbol CVM.ON BEHALF OF THE BOARD:(signed) 'Peter Bakema'CEO, President & DirectorFor further information contact:Brisco Capital Partners Corp.Scott Koyich, PresidentTelephone: (403) 262-9888This press release contains forward-looking information that involvesvarious risks and uncertainties regarding future events related to theJoint Venture. Such statements are subject to risks and uncertainties thatmay cause actual results, performance or developments to differ materiallyfrom those contained in the statements and are not guarantees of futureperformance of the Company. No assurance can be given that any of theevents anticipated by the forward-looking statements will occur or, if theydo occur, what benefits the Company will obtain from them. Theseforward-looking statements reflect management's current views and are basedon certain expectations, estimates and assumptions which may prove to beincorrect. A number of risks and uncertainties could cause our actualresults to differ materially from those expressed or implied by theforward-looking statements, including: (1) a downturn in general economicconditions in North America and internationally, (2) the inherentuncertainties and speculative nature associated with commercialization oftechnology and the practice of medicine, (3) a change in healthregulations, (4) any number of events or causes which may delay or ceasecommercialization and development of the Joint Venture, (5) the risk thatthe Company or the Joint Venture does not execute its business plan, (6)inability to retain key employees, (7) inability to finance operations andgrowth, and (8) other factors beyond the Company's control. Theseforward-looking statements are made as of the date of this news releaseand, except as required by law, the Company assumes no obligation to updatethese forward-looking statements, or to update the reasons why actualresults differed from those projected in the forward-looking statements.THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THECONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITSREGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OFTHE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY ORACCURACY OF THIS RELEASE.			Click on, or paste the following link into your web browser, to viewthe associated documentshttp://www.newsfilecorp.com/release/24472News Source: Newsfile---------------------------------------------------------------------------12.01.2017 Dissemination of a Corporate News, transmitted by DGAP - aservice of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements,Financial/Corporate News and Press Releases.Archive at www.dgap.de---------------------------------------------------------------------------     Language:    English     Company:     CVR Medical Corp.                  Canada     ISIN:        CA1266321084     End of News    DGAP News Service
Page: 1
Related Keywords:

Source:Copyright (c) EQS One. All Rights Reserved

Our Privacy Policy --- @ Copyright, 2017 Digital Media Online, All Rights Reserved